Open Forum Infectious Diseases最新文献

{"title":"Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Abdullah Tarik Aslan, Lokman Hekim Tanriverdi, Adrian V Hernandez, Umut Akova, Kursat Kutluca, Samuel Chan, Julien Coussement, Arreola Guerra Jose Manuel, Julia Origüen, Núria Sabé, Patrick N A Harris, Murat Akova, David L Paterson","doi":"10.1093/ofid/ofaf502","DOIUrl":"10.1093/ofid/ofaf502","url":null,"abstract":"<p><strong>Background: </strong>Asymptomatic bacteriuria (ASB) is generally systematically screened and treated with antibiotics in kidney transplant recipients (KTRs). We aimed to explore the role of antibiotic therapy in management of ASB in KTRs.</p><p><strong>Methods: </strong>Randomized controlled trials conducted through 10 May 2023 were searched on Ovid MEDLINE, Web of Science, PubMed, and Cochrane CENTRAL. We used inverse variance random-effects models for all meta-analyses; for rare outcomes, we used the Mantel-Haenszel method. ROB-2 criteria were used to assess the risk of bias.</p><p><strong>Results: </strong>We identified 4 randomized controlled trials (including 478 participants). Antibiotic therapy, compared with no therapy, nonsignificantly increased the risk of acute pyelonephritis by 19% (relative risk, 1.19 [95% confidence interval (CI)], .72-1.94; <i>I</i> ² = 0%) and that of symptomatic urinary tract infection (UTI) by 18% (1.18 [.78-1.78]; <i>I</i> ² = 28%). The risks of all-cause mortality (relative risk, 1.56 [95% CI, .54-4.52]), graft loss (0.80 [.20-3.19]), graft rejection (0.89 [.46-1.70]), hospital admission due to symptomatic UTI (0.92 [.48-1.76]), symptomatic UTI caused by a multidrug-resistant organism (1.31 [.63-2.74]), <i>Clostridioides difficile</i> diarrhea (0.75 [.23-2.42]), and serious adverse events (1.20 [.75-1.91]) did not differ significantly between groups, nor did the change in serum creatinine level from baseline to the end of the study (mean difference, 0.40 mg/dL [95% CI, -.05 to .85 mg/dL]). No significant differences were demonstrated in any outcomes between antibiotic therapy and no-therapy arms across subgroup and sensitivity analyses.</p><p><strong>Conclusions: </strong>Current evidence does not support routine screening and treatment of posttransplant ASB in KTRs.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 9","pages":"ofaf502"},"PeriodicalIF":3.8,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of Different Versions of Duke Criteria in Diagnosing Infective Endocarditis in Patients With Intracardiac Prosthetic Materials.","authors":"Matthaios Papadimitriou-Olivgeris, Bruno Ledergerber, Jana Epprecht, Berit Siedentop, Pierre Monney, Michelle Frank, Georgios Tzimas, Nicolas Fourré, Virgile Zimmermann, Giulia Domenichini, Lars Niclauss, Matthias Kirsch, Mathias Van Hemelrijck, Omer Dzemali, Benoit Guery, Barbara Hasse","doi":"10.1093/ofid/ofaf507","DOIUrl":"10.1093/ofid/ofaf507","url":null,"abstract":"<p><strong>Background: </strong>Diagnosing infective endocarditis (IE) is a significant challenge. This study aimed to compare the diagnostic performance of the 2015 and 2023 European Society of Cardiology (ESC) and the 2023 International Society for Cardiovascular Infectious Diseases (ISCVID) Duke clinical criteria in a cohort of patients with suspected IE and intracardiac prosthetic material.</p><p><strong>Methods: </strong>This retrospective study was conducted at 2 Swiss University Hospitals (2014-2024). The reference standard was the diagnosis of the Endocarditis Team or expert clinicians. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives.</p><p><strong>Results: </strong>Of the 1025 episodes with suspected IE and intracardiac prosthetic material, 537 (61%) had IE. Using the 2015 ESC, 2023 ESC, and 2023 ISCVID clinical criteria, 324 (32%), 367 (36%), and 430 (42%) episodes were classified as definite IE, respectively. The sensitivity for the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID the clinical criteria was calculated to be 56% (95% CI: 52-60%), 61% (57-65%), and 71% (67-74%), respectively, while the specificity 67% (63-71%), 56% (51-61%), and 34% (29-38%), respectively.</p><p><strong>Conclusions: </strong>The 2023 ISCVID Duke clinical criteria demonstrated the highest sensitivity for diagnosing IE compared to the 2015 and 2023 ESC Duke criteria in patients with intracardiac prosthetic material. However, this was at the expense of specificity.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 9","pages":"ofaf507"},"PeriodicalIF":3.8,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series.","authors":"Ana Moreno, Ruben Fernandez-Ibanez, Santos Del Campo, Maria J Perez-Elias, Jose L Casado, Miguel Garcia, Manuel Velez, Maria J Vivancos, Santiago Moreno","doi":"10.1093/ofid/ofaf470","DOIUrl":"10.1093/ofid/ofaf470","url":null,"abstract":"<p><strong>Background: </strong>Managing individuals with both HIV infection and a history of solid organ transplantation presents unique challenges due to interactions between antiretroviral therapy and immunosuppressive regimens. Long-acting injectable therapies may offer advantages in reducing drug interactions and improving adherence.</p><p><strong>Methods: </strong>This retrospective study assessed the virological efficacy and safety of long-acting injectable therapy with a combination of 2 antiviral agents in 5 patients with stable HIV infection who had undergone kidney or liver transplantation. Patients were followed for up to 74 weeks after initiating therapy. Virological response, immunological parameters, renal and hepatic function, and immunosuppressive drug levels were monitored.</p><p><strong>Results: </strong>All patients maintained undetectable viral loads throughout the study period, with no virological failure or drug-resistance development. CD4⁺ T-cell counts remained stable, and no clinically significant changes in renal or hepatic function were observed. Immunosuppressive drug levels remained within the therapeutic range without requiring dose adjustments. No patient experienced severe adverse effects or injection-site complications, and adherence was high throughout the study.</p><p><strong>Conclusions: </strong>Long-acting injectable therapy was effective and well tolerated in individuals with stable HIV infection following solid organ transplantation. The findings suggest that this approach may be a viable treatment option, reducing drug interactions while maintaining virological suppression. Further research with larger cohorts is needed to confirm these findings and establish guidelines for implementation in transplant recipients.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf470"},"PeriodicalIF":3.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial Usage Among Acutely Ill Hospitalized Children Aged 2‒23 Months in Sub-Saharan Africa and South Asia.","authors":"Carilie Tigoi, Celine Bourdon, Moses Ngari, Robert Musyimi, Molly Timbwa, Shalton Mwaringa, Narshion Ngao, Christopher Maronga, Moses Mburu, Agnes Ndirangu, Fehmina Arif, Zaubina Kazi, Muzammil Shabana Ejaz, Ali Faisal Saleem, Benson O Singa, Ezekiel Mupere, Abu Sadat Mohammad Sayeem Bin Shahid, Al Fazal Khan, Mohammod Jobayer Chisti, Tahmeed Ahmed, Christina Lancioni, Abdoulaye Diallo, Wieger Voskuijl, Robert H Bandsma, Kirkby D Tickell, Priya Sukhtanar, Judd L Walson, Nicole Stoesser, James A Berkley","doi":"10.1093/ofid/ofaf487","DOIUrl":"10.1093/ofid/ofaf487","url":null,"abstract":"<p><strong>Background: </strong>Understanding patterns of antimicrobial use is critical to supporting antibiotic stewardship and limiting antimicrobial resistance (AMR). We aimed to describe antimicrobial prescribing in acutely ill hospitalized children aged 2-23 months across a range of rural and urban hospital settings in Sub-Saharan Africa and South Asia.</p><p><strong>Methods: </strong>The Childhood Acute Illness & Nutrition (CHAIN) cohort collected data daily throughout hospitalization from children with acute illness aged 2-23 months admitted to 9 hospitals from November 2016 to January 2019. We determined proportions of children receiving antimicrobials, inpatient-days receiving antimicrobials, antimicrobial classes, World Health Organization (WHO) Access, Watch, and Reserve (AWaRe) classifications, and examined factors associated with Watch antimicrobial use.</p><p><strong>Results: </strong>Of 3101 admissions, 1422 (46%) received antimicrobials before hospitalization. A total of 2816 (91%) children received antimicrobials during 19 398/21 807 (93%) inpatient child-days. Two thousand four hundred seventy-seven (76%), 1092 (35%), and 12 (0.3%) children received Access, Watch, and Reserve antimicrobials, mostly within 48 hours of admission. Three hundred forty-one (11%) admissions received an antimicrobial without any indication. Prior admission, chronic illness, diagnoses of sepsis or meningitis, hypoglycemia, and duration of admission were associated with receiving Watch antimicrobials, while WHO danger signs, severe malnutrition, HIV, and receipt of prior antimicrobials were not, despite their known association with mortality and AMR.</p><p><strong>Conclusions: </strong>Antimicrobial use was similar across sites, with some overuse and notably limited escalation and de-escalation, likely due to guideline adherence. Guidelines need updating for the absence of relevant antimicrobial sensitivities, to include risk-based antimicrobial prescribing considering mortality risk and prior exposure to antimicrobials and the hospital environment. Hence, clinical trials of risk-differentiated care are needed.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 9","pages":"ofaf487"},"PeriodicalIF":3.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Delays in Diagnosis on Healthcare Costs Associated With Blastomycosis, Coccidioidomycosis, and Histoplasmosis in a Commercially Insured Population.","authors":"Kaitlin Benedict, Jason Massey, Michelle Fearon Scales, Ian Hennessee, Samantha L Williams, Mitsuru Toda","doi":"10.1093/ofid/ofaf499","DOIUrl":"10.1093/ofid/ofaf499","url":null,"abstract":"<p><p>Among patients with blastomycosis (<i>n</i> = 281), coccidioidomycosis (<i>n</i> = 1920), and histoplasmosis (<i>n</i> = 2180), 62% experienced diagnostic delays (mean 29 days). Patients who experienced delays incurred average excess healthcare costs of up to $15 648 (95% confidence interval: $8600-$22 695) compared with those without a delay. Earlier diagnosis may help reduce excess costs.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf499"},"PeriodicalIF":3.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends Analysis of Sexually Transmitted Infections Before and After Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States 2001-2022.","authors":"Zailing Xing, Daniel Escudero","doi":"10.1093/ofid/ofaf491","DOIUrl":"10.1093/ofid/ofaf491","url":null,"abstract":"<p><strong>Background: </strong>The correlation between human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) usage and sexually transmitted infections (STIs) remains equivocal. Limited studies have investigated national STI trends after introducing PrEP. We aimed to examine STI incidence before and after PrEP introduction and explore correlations with PrEP use in the United States.</p><p><strong>Methods: </strong>PrEP usage data (2012-2022) were obtained from AIDSVu, and STI data (2001-2022) from the Centers for Disease Control and Prevention's STI Statistics Archive. We used the coefficient of determination to estimate variance in STI rates explained by PrEP usage. We used cross-correlation to identify lagged correlations and segmented linear regression to examine STI trends by demographics before and after PrEP initiation.</p><p><strong>Results: </strong>Syphilis rates increased by 0.2/100 000 people annually before 2012 and by 1.4/100 000 persons after PrEP introduction. Gonorrhea rates dropped by 2.9/100 000 people before 2012 but rose by 14/100 000 afterward. The slope for chlamydia dropped from 20.9 to 6.6. The coefficients of determination for syphilis, gonorrhea, and chlamydia attributable to PrEP usage were 0.98, 0.88, and 0.2, respectively. Lagged correlations were significant for chlamydia, but not for syphilis and gonorrhea. Overall, STI rates were more strongly correlated with PrEP usage among males than females.</p><p><strong>Conclusions: </strong>We found significant changes in the rate of incident STIs from 2012 to 2022 and a high correlation between PrEP usage and reported cases of syphilis and gonorrhea. Given the role of PrEP in comprehensive HIV prevention in the United States, its impact on rates of STI infection should be further studied.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 9","pages":"ofaf491"},"PeriodicalIF":3.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Machine Learning-Based Screening Algorithm to Predict High-Risk Hepatitis C Infection.","authors":"Suk-Chan Jang, Wei-Hsuan Lo-Ciganic, Pilar Hernandez-Con, Chanakan Jenjai, James Huang, Ashley Stultz, Shunhua Yan, Debbie L Wilson, Ashley Norse, Faheem W Guirgis, Robert L Cook, Christine Gage, Khoa A Nguyen, Patrick Hornes, Yonghui Wu, David R Nelson, Haesuk Park","doi":"10.1093/ofid/ofaf496","DOIUrl":"10.1093/ofid/ofaf496","url":null,"abstract":"<p><strong>Background: </strong>Amid the opioid epidemic in the United States, hepatitis C virus (HCV) infections are rising, with one-third of individuals with infection unaware due to the asymptomatic nature. This study aimed to develop and validate a machine learning (ML)-based algorithm to screen individuals at high risk of HCV infection.</p><p><strong>Methods: </strong>We conducted prognostic modeling using the 2016-2023 OneFlorida+ database of all-payer electronic health records. The study included individuals aged ≥18 years who were tested for HCV antibodies, RNA, or genotype. We identified 275 features of HCV, including sociodemographic and clinical characteristics, during a 6-month period before the test result date. Four ML algorithms-elastic net (EN), random forest (RF), gradient boosting machine (GBM), and deep neural network (DNN)-were developed and validated to predict HCV infection. We stratified patients into deciles based on predicted risk.</p><p><strong>Results: </strong>Among 445 624 individuals, 11 823 (2.65%) tested positive for HCV. Training (75%) and validation (25%) samples had similar characteristics (mean, standard deviation age, 45 [16] years; 62.86% female; 54.43% White). The GBM model (<i>C</i> statistic, 0.916 [95% confidence interval = .911-.921]) outperformed the EN (0.885 [.879-.891]), RF (0.854 [.847-.861]), and DNN (0.908 [.903-.913]) models (<i>P</i> < .0001). Using the Youden index, GBM achieved 79.39% sensitivity and 89.08% specificity, identifying 1 positive HCV case per 6 tests. Among patients with HCV, 75.63% and 90.25% were captured in the top first and first to third risk deciles, respectively.</p><p><strong>Conclusions: </strong>ML algorithms effectively predicted and stratified HCV infection risk, offering a promising targeted screening tool for clinical settings.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf496"},"PeriodicalIF":3.8,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evidence-Based Intervention to Increase <i>Trypanosoma cruzi</i>, a Neglected Parasitic Infection, Diagnosis in Rural and Moderate-Size-City US Clinics.","authors":"M K Lynn, Hunter M Boehme, Jeffrey Hall, Patrick Kent, Alain H Litwin, Quang H Pham, Melissa S Nolan","doi":"10.1093/ofid/ofaf467","DOIUrl":"10.1093/ofid/ofaf467","url":null,"abstract":"<p><strong>Background: </strong>Chagas disease is a chronic, insidious parasitic infection (<i>Trypanosoma cruzi</i>) that slowly develops to irreversible organomegaly over several decades. The disease is traditionally acquired in endemic Latin American countries during childhood; <1% of foreign-born adult residents in the United States have been diagnosed or treated with this potentially fatal disease. Low physician knowledge is a primary factor leading to misdiagnosis.</p><p><strong>Methods: </strong>Starting in April 2022, a 4-part <i>T cruzi</i> clinical education intervention began, which included (<i>i</i>) 2 grand rounds presentations to >100 internal medicine providers; (<i>ii</i>) implementation of a \"clinical Chagas champions program\" incorporating 14 key clinical staff at varying departments and administrative levels educated on their specific role related to <i>T cruzi</i> screening, diagnosis confirmation, clinical management, and medical billing; (<i>iii</i>) connecting clinicians with external, experienced providers to provide guidance during the medically challenging treatment process; and (<i>iv</i>) <i>T cruzi</i> patient screening at Prisma Health hospitals, family medicine clinics, or affiliated free health clinics. The program's long-term impact was evaluated using a panel Poisson time series statistical model of ordered tests pre- and post-intervention.</p><p><strong>Results: </strong>For the healthcare system screening initiative, 71 participants were enrolled from across Prisma Health's 21-county region, with a 2.9% Chagas disease seroprevalence detected. Time series analysis of <i>T cruzi</i> testing orders within the healthcare system demonstrated a statistically significant increase in ordered tests across the 30 months post-intervention compared to the 51 months prior.</p><p><strong>Conclusions: </strong>This intervention substantiates the need to pair academic-health partnerships and clinical awareness campaigns to sustainably support long-term <i>T cruzi</i> screening in nontraditional areas.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf467"},"PeriodicalIF":3.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing the Optimal Ceftriaxone MIC for Predicting ESBL Production in Bloodstream Infections.","authors":"Dariusz A Hareza, Yehudit Bergman, Emily Jacobs, Amy J Mathers, Alan R Hauser, Sara E Cosgrove, Patricia J Simner, Pranita D Tamma","doi":"10.1093/ofid/ofaf490","DOIUrl":"10.1093/ofid/ofaf490","url":null,"abstract":"","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 9","pages":"ofaf490"},"PeriodicalIF":3.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition.","authors":"Yijia Li, Michael B Townsend, Shanshan Li, Quinn E Testa, Tom Medvec, Elizabeth A Thompson, Frank J Palella, Matthew J Mimiaga, James B Brock, Maria L Alcaide, Anandi N Sheth, Michelle Floris-Moore, Aruna Chandran, Audrey L French, Phyllis C Tien, Daniel J Merenstein, Michael Augenbraun, Anjali Sharma, Caitlin A Moran, Charles R Rinaldo, Bernard J C Macatangay, Panayampalli S Satheshkumar, Ken S Ho","doi":"10.1093/ofid/ofaf497","DOIUrl":"10.1093/ofid/ofaf497","url":null,"abstract":"<p><p>Little is known about the serologic response elicited by the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination (JYNNEOS) against mpox in elderly individuals with or without HIV. In this study, we measured levels of antibody against orthopoxvirus in selected participants (n = 114) with HIV or at risk for HIV acquisition from the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study, who had no prior reported history of mpox. Participants reported MVA-BN vaccination history via questionnaires. The median age was 64 years, 24.6% were female, and 46% were HIV seropositive. Twenty out of 114 participants received at least 1 dose of MVA-BN. We found that MVA-BN induced sustained IgG levels regardless of HIV status, even up to 1 year. Birth before 1973 was correlated with higher IgG. MVA-BN-unvaccinated individuals with HIV had lower IgG than those without HIV. Although limited by small sample size, our study is among the first to assess anti-orthopoxvirus antibodies specifically in a vulnerable, older population and stratified by HIV status.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf497"},"PeriodicalIF":3.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}